Evaluation of AP-002 in Patients With Solid Tumors

A Phase 1/2 Dose Escalation Study of AP-002 In Patients With Advanced or Recurrent Solid Tumors

The purpose of this trial is to define an effective and safe dose of AP-002 in advanced or recurrent solid tumors for which there are no standard therapies to use in subsequent studies in advanced or recurrent breast, non-small cell lung cancer (NSCLC) or prostate cancers.

Study Overview

• Status: Unknown
• Conditions: Solid Tumor
• Intervention / Treatment: Drug: AP-002

Detailed Description

The Phase 1 portion of this study will determine the Pharmacodynamically Active Dose (PAD) of AP-002 in humans, defined as the dose at which the plasma concentration of AP-002, as measured by Ga, is 300-500 ng/mL and which is at or below the Maximum Tolerated Dose (MTD), to use in the clinical setting of advanced or recurrent solid tumors. This will be followed by a Phase 2 expanded cohort treated at the PAD, to estimate the efficacy of AP-002 in patients with advanced or recurrent breast cancer, NSCLC and prostate cancer.

Patients will receive AP-002 orally, once daily for 14 days of a 21 day cycle.

• Study Type: Interventional
• Enrollment (Anticipated): 61
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60208
      • Not yet recruiting
      • Research Institution
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Recruiting
      • Research Site
  • Texas
    • Houston, Texas, United States, 77030
      • Recruiting
      • Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Phase 1: Patients with advanced or recurrent solid tumors with target (± non-target) or with only non-target disease, for which there is no standard therapy available Phase 2: Patients with advanced or recurrent breast cancer, NSCLC, or prostate cancer with target (± non-target) or with only non-target disease for which there is no standard therapy available
2. Patients with bone metastases but without target disease are eligible
3. Patients with bone metastases must have at least one bone lesion that has not received radiation therapy within 6 weeks prior to Cycle 1 Day 1
4. Patients must discontinue bisphosphonate and/or denosumab treatment.
5. Age ≥ 18 years
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
7. O2 saturation ≥ 92% on room air per pulse oximetry
8. Exhaled nitrous oxide ≤ 50 parts per billion (ppb)

9. Adequate hematologic, hepatic and renal function defined as:

   1. Hemoglobin ≥ 9 g/dL
   2. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L
   3. Platelet count ≥ 75 × 109/L
   4. Total bilirubin ≤ 2 × upper limit of normal (ULN). Patients with an established diagnosis of Gilberts syndrome with an unconjugated bilirubin ≤ 2 mg/dL and conjugated bilirubin within normal limits (WNL) are eligible.
   5. Serum electrolytes WNL
   6. Transaminases ≤ 3 × ULN
   7. Prothrombin time (PT)/international normalized ratio (INR), thromboplastin time (PTT), or activated PTT (aPTT) ≤ 1.5 × ULN. For patients on therapeutic coumadin, PT (INR) ≤ 2.5 × ULN is acceptable; for patients on therapeutic heparin, PTT (or aPTT) ≤ 2.5 × ULN
   8. Corrected creatinine clearance ≥ 40 mL/minute, based on the Cockcroft-Gault equation
10. Patient must have discontinued prior antineoplastic therapy at least 21 days prior to Cycle 1 Day 1 and have recovered or stabilized from any prior AEs related to the prior therapy
11. Provision of signed and dated informed consent form
12. Serum 25-hydroxyvitamin D ≥ 30 ng/mL by investigative site laboratory at screening

Exclusion Criteria:

1. Evidence of benign primary hyperparathyroidism, hyperthyroidism, adrenal insufficiency, vitamin D intoxication, mild alkali syndrome, sarcoidosis or other granulomatous disease
2. Treatment with calcitonin, mithramycin or cinacalcet within 7 days prior to the date of the screening
3. Receiving dialysis for renal failure
4. Patients with a known history of clinically significant active infection, including human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
5. Patients with active central nervous system (CNS) metastases are not eligible, but patients with treated, stable CNS metastases are allowed
6. Patients with QT interval of ≥ 480 msec on ECG
7. Patients with Paget's disease of bone
8. Patients of childbearing potential unwilling to abstain from sexual intercourse, or employ effective barrier methods of contraception during participation in this trial
9. Pregnancy or lactation. A negative pregnancy test will be required for women of childbearing potential prior to study enrollment and will be repeated throughout the study. Women of childbearing potential will be defined as women who have not had natural or pharmacologic menopause, nor surgical sterilization.
10. Patients unwilling or unable to take oral medication, requiring a nasogastric or gastrostomy tube, or unwilling to adhere to the treatment regimen and fasting requirements
11. Patients unwilling to comply with all study procedures or who are unavailable for the duration of the study
12. Known allergies to any components of the AP-002 Drug Product

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Interventional Model: SEQUENTIAL
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Tablets to be taken orally daily for 14 of 21 day cycle; AP-002 (4 mg and 20 mg tablets) to be taken orally daily for 14 days	Drug: AP-002; Dose escalation; Other Names: no other names

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety Assessment	Number of participants with treatment-related adverse events (safety and tolerability) as assessed by CTCAE v4.0	Through study completion/ up to 18 months
Dose Assessment	Define the recommended phase 2 dose	Up to 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy Assessment	Estimation of anti-tumor activity per RESIST v1.1	Through study completion/ up to 18 months
Efficacy Assessment	For patients with bone metastases, the time to new bone metastasis, progression of bone metastases, or other skeletal related events	Through study completion/ up to 18 months
Pharmacokinetic Assessment	Estimation of pharmacokinetic profile by evaluating maximum plasma concentration [Cmax]	Through study completion/ up to 18 months

Collaborators and Investigators

• Sponsor: Altum Pharmaceuticals INC
• Investigators: Study Chair: Angela Ogden, MD, Altum Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 27, 2019
• Primary Completion (ANTICIPATED): March 1, 2021
• Study Completion (ANTICIPATED): April 1, 2021

Study Registration Dates

• First Submitted: October 4, 2019
• First Submitted That Met QC Criteria: October 27, 2019
• First Posted (ACTUAL): October 29, 2019

Study Record Updates

• Last Update Posted (ACTUAL): October 31, 2019
• Last Update Submitted That Met QC Criteria: October 30, 2019
• Last Verified: October 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: ALT-002-SRE-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Diaries will be left at site and used as source documents

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No